A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma.

Cell Cycle
Zhihua ZhangLihong Wang

Abstract

This study aimed to explore the effect of GANT61 on regulating cell proliferation, cell apoptosis and cell cycle, and to investigate whether GANT61 would function in multiple myeloma (MM) via inhibiting Notch pathway. Methods: RPMI-8226 and U266 cells were treated by GANT61 (0, 2.5, 5.0, 10.0, 20.0, 30.0, 40.0, 50.0 μmol/L) for 18, 24 and 36 hours (h), and cell proliferation was detected by Cell Counting Kit 8. Then these cells were treated by GANT61 at 0, 2.5, 5.0, 10.0 μmol/L for 24 h or treated by 10.0 μmol/L GANT61 for 0, 18, 24 and 36 h, and cell apoptosis rate, apoptosis markers and cell cycle were detected by AV/PI, Western blot, and PI staining. Notch1, Jagged1, Jagged2 and Hes1 expressions were detected by qPCR and Western blot. Further rescue experiments were conducted by upregulating Notch1. Results: In RPMI-8226 and U266 cells, GANT61 inhibited cell proliferation, increased cell apoptosis rate and cell percentage of G1/G0 phase while decreased cell percentage of S phase in a dose- and time-dependent manner. Besides, GANT61 inhibited Notch1, Jagged1, Jagged2 and Hes1 expressions in a dose- and time-dependent manner as well. In rescue experiments, Notch1 upregulation attenuated the inhibition of cell proliferation, pr...Continue Reading

References

May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Matthias LauthRune Toftgård
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Apr 22, 2011·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Nikolaus Becker
Mar 13, 2014·Blood·Camille LobryIannis Aifantis
Mar 13, 2014·Cancer Treatment Reviews·Jillian BrechbielAlex A Adjei
Sep 27, 2014·Oncotarget·Michela ColomboRaffaella Chiaramonte
Dec 30, 2014·Lancet·Christoph RölligMartin Bornhäuser
Apr 4, 2015·Blood·Philippe MoreauThierry Facon
Jun 9, 2015·Oncotarget·Annelies GonnissenKarin Haustermans
Jan 23, 2016·Developmental Biology·Randy RinguetteValerie A Wallace
Feb 18, 2016·Stem Cells International·Ahmet AcarKeith Brennan
Mar 24, 2016·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Bing LongQuentin Liu
Jan 23, 2017·Journal of Hematology & Oncology·Riccardo MasettiAndrea Pession

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
transfection
Protein Assay

Software Mentioned

GraphPad
SPSS

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.